Absci (ABSI) unveiled new preclinical data for ABS-201, an AI-designed antibody targeting the prolactin receptor. The data demonstrate that ABS-201 effectively stimulates hair growth by regenerating the stem cell niche as well as promoting additional key growth modulators. Mechanistically, ABS-201 treatment significantly inhibited the prolactin receptor, or PRLR, signaling pathway. This inhibition correlated with prolongation of anagen and restoration of growth signaling, preservation and expansion of stem cell niche, potential for follicle reconversion, activity in endogenous settings. Together, data from these studies further validate the anti-PRLR mechanism in androgenetic alopecia. Absci anticipates an interim data readout from its Phase 1/2a HEADLINE study in the second half of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci, former U.S. soccer player Donovan announce partnership
- These 3 Under-the-Radar Stocks Have Triple-Digit Upside Potential – 12/5/2025
- Promising Developments in AbSci’s ABS-201 Program and Market Potential
- Absci announces first participants dosed in Phase 1/2a HEADLINE trial
- Strategic Focus on ABS-201 Drives Buy Rating for AbSci Amid Promising AGA and Endometriosis Market Opportunities